HC Wainwright & Co. Continues to Recommend Buying Sanara MedTech (SMTI)
Analyst Recommendation: HC Wainwright & Co. has maintained a Buy recommendation for Sanara MedTech, with an average one-year price target of $51.00/share, indicating a potential upside of 136.66% from its current price of $21.55/share.
Projected Revenue and EPS: Sanara MedTech is projected to achieve annual revenue of $160 million, reflecting a 64.97% increase, with a non-GAAP EPS forecast of 0.35.
Fund Sentiment: There are currently 140 funds reporting positions in Sanara MedTech, with a 1.45% increase in ownership over the last quarter and a significant rise in average portfolio weight dedicated to the company.
Shareholder Activity: Various institutional shareholders have adjusted their positions, with some increasing their holdings while others have decreased their portfolio allocations in Sanara MedTech over the last quarter.
Trade with 70% Backtested Accuracy
Analyst Views on SMTI
About SMTI
About the author
Sanara MedTech (SMTI) Projects Q4 2025 Revenue of $27.2M to $27.7M
- Revenue Growth Outlook: Sanara MedTech anticipates Q4 2025 net revenue between $27.2 million and $27.7 million, reflecting a year-over-year increase of approximately 3% to 5%, indicating stable growth potential in the market.
- BIASURGE Sales Recovery: The company experienced significant sales growth in its BIASURGE Advanced Surgical Solution due to supply chain issues in Q4 2024, with expected net revenue growth of approximately 11% to 13% year-over-year for Q4 2025.
- Annual Financial Guidance: For the full year 2025, net revenue is projected to range from $102.7 million to $103.2 million, representing a year-over-year increase of about 19%, reflecting ongoing growth in the surgical sector and recovering market demand.
- Future Projections: Sanara MedTech expects full year 2026 net revenue to range from $116 million to $121 million, indicating a growth of approximately 13% to 17% compared to the midpoint of the 2025 revenue forecast, showcasing confidence in future growth.
Sanara MedTech Secures Innovative Technology Contract with Vizient for BIASURGE
- Innovative Technology Contract: Sanara MedTech's BIASURGE Advanced Surgical Solution has secured a contract with Vizient, effective January 1, 2026, expanding the company's reach within a healthcare network representing over $156 billion in annual purchasing volume.
- Product Advantages: BIASURGE is a no-rinse irrigation solution designed to cleanse surgical wounds more effectively than saline alone, with its antimicrobial preservative providing broad-spectrum effectiveness that supports infection control strategies and enhances surgical precision.
- Market Potential: The contract was awarded based on recommendations from hospital experts, indicating BIASURGE's unique qualities and potential to improve surgical care, which could significantly enhance the company's market competitiveness and sales.
- Portfolio Expansion: Sanara MedTech also markets CellerateRX Surgical Activated Collagen Powder, FORTIFY tissue repair grafts, and advanced biologic matrices, aimed at improving clinical outcomes while reducing healthcare costs, further solidifying its position in the surgical products market.
Sanara MedTech (SMTI) Announces IPREMIUM Upgrade for BIASURGE Surgical Solution
- Product Upgrade: Sanara MedTech announced that its BIASURGE Advanced Surgical Solution has received an IPREMIUM upgrade, enhancing the product's market competitiveness and expected to improve customer experience.
- Market Impact: This upgrade may attract more healthcare institutions to adopt the solution, potentially driving sales growth in the surgical medical device market and further solidifying the company's market position.
- Technological Innovation: The upgrade of BIASURGE reflects Sanara MedTech's ongoing innovation in surgical technology, aimed at meeting evolving medical needs and enhancing surgical efficiency.
- Strategic Significance: Through this upgrade, Sanara MedTech not only increases the product's added value but also lays the groundwork for future R&D and market expansion, enhancing the company's long-term growth potential.
Investor Notice: Holzer & Holzer, LLC Launches Investigation into Sanara MedTech Inc. (SMTI)
Investigation Announcement: Holzer & Holzer, LLC is investigating Sanara MedTech Inc. for potential violations of federal securities laws following the company's announcement of a strategic realignment and discontinuation of its Tissue Health Plus operations, which led to a drop in stock price.
Investor Outreach: Investors who purchased Sanara stock and experienced losses are encouraged to contact Holzer & Holzer for legal assistance regarding their rights.
Law Firm Background: Holzer & Holzer, LLC is a highly rated securities litigation law firm that has successfully recovered significant amounts for shareholders affected by corporate misconduct since its establishment in 2000.
Contact Information: Interested parties can reach out to Corey Holzer or Joshua Karr via email or phone for more information about the investigation and potential legal actions.
Sanara MedTech to Attend the 37th Annual Healthcare Conference Hosted by Piper Sandler on December 3rd
Company Participation in Conference: Sanara MedTech Inc. will present at the Piper Sandler 37th Annual Healthcare Conference in New York from December 2-4, 2025, with a scheduled presentation on December 3 at 9:30 a.m. ET.
Product Offerings: The company specializes in developing and marketing surgical products aimed at improving clinical outcomes and reducing healthcare costs, with a focus on the North American surgical tissue repair market.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's business strategy, product development, and potential risks associated with regulatory approvals and market acceptance.
Investor Relations: Additional information and presentation materials will be available on the company's investor relations website, along with a live audio webcast and an archive for later access.
Sanara MedTech (SMTI) Shifts Focus Following THP Division Closure and Quarterly Losses
Sanara MedTech's Business Realignment: The company has discontinued its Tissue Health Plus division to focus on its core surgical segment, reporting third-quarter earnings of $26.33 million in sales and a net loss of $30.41 million.
Future Growth Projections: Sanara anticipates $144.9 million in revenue and $1.9 million in earnings by 2028, based on a projected annual revenue growth rate of 14.2%, with a fair value estimate ranging from $18.41 to $41.00 per share.
Impact on Investment Outlook: Investors need to consider the potential of Sanara's surgical segment for future profitability, as the exit from THP addresses short-term risks but may affect resource allocation and operational priorities.
Market Sentiment and Analysis: The article emphasizes the importance of ongoing net losses and business realignment on future earnings, while also providing a comprehensive analysis of Sanara MedTech's financial health for potential investors.
Sanara MedTech (SMTI) Projects Q4 2025 Revenue of $27.2M to $27.7M
- Revenue Growth Outlook: Sanara MedTech anticipates Q4 2025 net revenue between $27.2 million and $27.7 million, reflecting a year-over-year increase of approximately 3% to 5%, indicating stable growth potential in the market.
- BIASURGE Sales Recovery: The company experienced significant sales growth in its BIASURGE Advanced Surgical Solution due to supply chain issues in Q4 2024, with expected net revenue growth of approximately 11% to 13% year-over-year for Q4 2025.
- Annual Financial Guidance: For the full year 2025, net revenue is projected to range from $102.7 million to $103.2 million, representing a year-over-year increase of about 19%, reflecting ongoing growth in the surgical sector and recovering market demand.
- Future Projections: Sanara MedTech expects full year 2026 net revenue to range from $116 million to $121 million, indicating a growth of approximately 13% to 17% compared to the midpoint of the 2025 revenue forecast, showcasing confidence in future growth.
Sanara MedTech Secures Innovative Technology Contract with Vizient for BIASURGE
- Innovative Technology Contract: Sanara MedTech's BIASURGE Advanced Surgical Solution has secured a contract with Vizient, effective January 1, 2026, expanding the company's reach within a healthcare network representing over $156 billion in annual purchasing volume.
- Product Advantages: BIASURGE is a no-rinse irrigation solution designed to cleanse surgical wounds more effectively than saline alone, with its antimicrobial preservative providing broad-spectrum effectiveness that supports infection control strategies and enhances surgical precision.
- Market Potential: The contract was awarded based on recommendations from hospital experts, indicating BIASURGE's unique qualities and potential to improve surgical care, which could significantly enhance the company's market competitiveness and sales.
- Portfolio Expansion: Sanara MedTech also markets CellerateRX Surgical Activated Collagen Powder, FORTIFY tissue repair grafts, and advanced biologic matrices, aimed at improving clinical outcomes while reducing healthcare costs, further solidifying its position in the surgical products market.
Sanara MedTech (SMTI) Announces IPREMIUM Upgrade for BIASURGE Surgical Solution
- Product Upgrade: Sanara MedTech announced that its BIASURGE Advanced Surgical Solution has received an IPREMIUM upgrade, enhancing the product's market competitiveness and expected to improve customer experience.
- Market Impact: This upgrade may attract more healthcare institutions to adopt the solution, potentially driving sales growth in the surgical medical device market and further solidifying the company's market position.
- Technological Innovation: The upgrade of BIASURGE reflects Sanara MedTech's ongoing innovation in surgical technology, aimed at meeting evolving medical needs and enhancing surgical efficiency.
- Strategic Significance: Through this upgrade, Sanara MedTech not only increases the product's added value but also lays the groundwork for future R&D and market expansion, enhancing the company's long-term growth potential.
Investor Notice: Holzer & Holzer, LLC Launches Investigation into Sanara MedTech Inc. (SMTI)
Investigation Announcement: Holzer & Holzer, LLC is investigating Sanara MedTech Inc. for potential violations of federal securities laws following the company's announcement of a strategic realignment and discontinuation of its Tissue Health Plus operations, which led to a drop in stock price.
Investor Outreach: Investors who purchased Sanara stock and experienced losses are encouraged to contact Holzer & Holzer for legal assistance regarding their rights.
Law Firm Background: Holzer & Holzer, LLC is a highly rated securities litigation law firm that has successfully recovered significant amounts for shareholders affected by corporate misconduct since its establishment in 2000.
Contact Information: Interested parties can reach out to Corey Holzer or Joshua Karr via email or phone for more information about the investigation and potential legal actions.
Sanara MedTech to Attend the 37th Annual Healthcare Conference Hosted by Piper Sandler on December 3rd
Company Participation in Conference: Sanara MedTech Inc. will present at the Piper Sandler 37th Annual Healthcare Conference in New York from December 2-4, 2025, with a scheduled presentation on December 3 at 9:30 a.m. ET.
Product Offerings: The company specializes in developing and marketing surgical products aimed at improving clinical outcomes and reducing healthcare costs, with a focus on the North American surgical tissue repair market.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's business strategy, product development, and potential risks associated with regulatory approvals and market acceptance.
Investor Relations: Additional information and presentation materials will be available on the company's investor relations website, along with a live audio webcast and an archive for later access.
Sanara MedTech (SMTI) Shifts Focus Following THP Division Closure and Quarterly Losses
Sanara MedTech's Business Realignment: The company has discontinued its Tissue Health Plus division to focus on its core surgical segment, reporting third-quarter earnings of $26.33 million in sales and a net loss of $30.41 million.
Future Growth Projections: Sanara anticipates $144.9 million in revenue and $1.9 million in earnings by 2028, based on a projected annual revenue growth rate of 14.2%, with a fair value estimate ranging from $18.41 to $41.00 per share.
Impact on Investment Outlook: Investors need to consider the potential of Sanara's surgical segment for future profitability, as the exit from THP addresses short-term risks but may affect resource allocation and operational priorities.
Market Sentiment and Analysis: The article emphasizes the importance of ongoing net losses and business realignment on future earnings, while also providing a comprehensive analysis of Sanara MedTech's financial health for potential investors.
